Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Raptor Pharmaceutical Corp.

Division of Horizon Therapeutics PLC
www.raptorpharma.com

Latest From Raptor Pharmaceutical Corp.

Finance Watch: Investment In Novel Antibacterials Gets A New Boost With Qpex Launch

Repeat antibiotic entrepreneurs raised $33m to launch Qpex with assets from The Medicines Co. Also, Taiho increases VC fund to $300m and TP Therapeutics raises $80m.

Financing StartUps and SMEs

Scrip 100 Analysis: Sales Up, Profits Down – But Is It Real?

Bellwethers tell you something, but to gauge the health of the pharmaceutical industry, you really need the Scrip 100. For FY 2016, it looks like drug sales are up again and profits are down. But is this what's actually going on?

Scrip 100 Sales & Earnings

Mercaptor Wants To Reinvent Drug Discovery And Development With No Pharma Or VC Funding

Emerging Company Profile: Mercaptor – a California company that emerged from Raptor Pharmaceutical, which Horizon Pharma bought for $800m in 2016 – has grandiose plans to create a new therapy for neurodegenerative disorders with only scientists running the show and no pharma or VC backing.

StartUps and SMEs Neurology

Horizon's Poor Primary Care Performance Overshadows River Vision Buy

Horizon's deal to buy River Vision to bolster its orphan product pipeline is cast into the shade by a disappointing first quarter performance for its primary care business.

Deals Sales & Earnings
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Metabolic Disorders
  • Neurology, Nervous System
  • Alias(es)
  • Raptor Pharmaceutical Inc.
  • Raptor Pharmaceuticals Corp.
  • TorreyPines Therapeutics Inc.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Horizon Therapeutics PLC
  • Senior Management
  • Julie Anne Smith, Pres. & CEO
    Michael P Smith, CFO
    Todd C Zankel, PhD, CSO
    David A Happel, Chief Commercial Officer
    Kimberly Lee, DO, VP, Corp. Strategy & Communications
    Krisha R Polu, MD, CMO
    Joel M Rothman, VP, Dev. Operations
  • Contact Info
  • Raptor Pharmaceutical Corp.
    Phone: (415) 408-6200
    7 Hamilton Landing
    Ste. 100
    Novato, CA 94949
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register